Suppr超能文献

组胺对脂蛋白代谢的新作用:抑制大鼠肝脏低密度脂蛋白受体表达并降低血浆高密度脂蛋白胆固醇水平

Novel effects of histamine on lipoprotein metabolism: suppression of hepatic low density lipoprotein receptor expression and reduction of plasma high density lipoprotein cholesterol in the rat.

作者信息

Liao W, Rudling M, Angelin B

机构信息

Department of Medicine, Karolinska Institute, Huddinge University Hospital, Sweden.

出版信息

Endocrinology. 1997 May;138(5):1863-70. doi: 10.1210/endo.138.5.5115.

Abstract

Histamine has been shown to be involved in atherosclerosis and coronary heart disease. Little information is available regarding the effects of histamine on lipoprotein metabolism. In the current study, we investigated the effects of histamine on the expression of hepatic low density lipoprotein (LDL) receptors and on plasma lipoproteins in the rat. Injection of compound 48/80 (C48/80, a histamine releaser) or histamine reduced hepatic LDL receptor expression, but not LDL receptor messenger RNA levels. Oral administration of polymyxin B (an antiendotoxin antibiotic and a histamine releaser) before the injection of C48/80 or histamine did not attenuate their effects. Polymyxin B itself had effects similar to those of C48/80 and histamine on LDL receptors. These results suggest that the effects of histamine are not mediated by the induction of gut-derived endotoxemia. Histamine H2 agonists (dimaprit and impromidine), but not H1 agonists (2-methylhistamine and 2-thiazolylethylamine), also reduced hepatic LDL receptor expression. The suppressive effect of C48/80 on hepatic LDL receptor expression was not attenuated by either the H1 antagonist (chlorpheniramine) or the H2 antagonist (cimetidine). Administration of C48/80 also reduced plasma high density lipoprotein (HDL) cholesterol. The H1 antagonist (chlorpheniramine), but not the H2 antagonist (cimetidine), almost completely reversed the effect of C48/80 on plasma HDL cholesterol. In conclusion, histamine suppresses hepatic LDL receptor expression via a non-H1 receptor-mediated pathway, and histamine reduces plasma HDL cholesterol via an H1 receptor-mediated pathway.

摘要

组胺已被证明与动脉粥样硬化和冠心病有关。关于组胺对脂蛋白代谢的影响,目前可用信息较少。在本研究中,我们研究了组胺对大鼠肝脏低密度脂蛋白(LDL)受体表达及血浆脂蛋白的影响。注射化合物48/80(C48/80,一种组胺释放剂)或组胺可降低肝脏LDL受体表达,但不影响LDL受体信使核糖核酸水平。在注射C48/80或组胺之前口服多粘菌素B(一种抗内毒素抗生素及组胺释放剂)并不能减弱它们的作用。多粘菌素B本身对LDL受体的作用与C48/80和组胺相似。这些结果表明,组胺的作用不是由肠道源性内毒素血症的诱导介导的。组胺H2激动剂(二甲双胍和英普咪定)可降低肝脏LDL受体表达,而H1激动剂(2-甲基组胺和2-噻唑基乙胺)则不能。C48/80对肝脏LDL受体表达的抑制作用,既不被H1拮抗剂(氯苯那敏)也不被H2拮抗剂(西咪替丁)减弱。注射C48/80还可降低血浆高密度脂蛋白(HDL)胆固醇。H1拮抗剂(氯苯那敏)几乎完全逆转了C48/80对血浆HDL胆固醇的作用,而H2拮抗剂(西咪替丁)则不能。总之,组胺通过非H1受体介导的途径抑制肝脏LDL受体表达,组胺通过H1受体介导的途径降低血浆HDL胆固醇。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验